Evidence map›Paper›PMID 30849944›Full record

ArticleBMC cancer2019

Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes.

Neeraj Kumar, Dan Zhao, Dulal Bhaumik, Amit Sethi, Peter H Gann

Abstract read
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Neeraj KumarDepartment of Pathology, College of Medicine, University of Illinois at Chicago, 840 S. Wood Street, MC 847, Chicago, IL, 60612, USA.
Dan ZhaoDivision of Epidemiology and Biostatistics, School of Public Health, University of Illlinois at Chicago, 1603 W. Taylor Street, MC 923, Chicago, IL, 60612, USA.
Dulal BhaumikDivision of Epidemiology and Biostatistics, School of Public Health, University of Illlinois at Chicago, 1603 W. Taylor Street, MC 923, Chicago, IL, 60612, USA.
Amit SethiDepartment of Pathology, College of Medicine, University of Illinois at Chicago, 840 S. Wood Street, MC 847, Chicago, IL, 60612, USA.
Peter H GannDepartment of Pathology, College of Medicine, University of Illinois at Chicago, 840 S. Wood Street, MC 847, Chicago, IL, 60612, USA. pgann@uic.edu.ORCID http://orcid.org/0000-0002-9439-2900

Funding

Breast Cancer Alliance Exceptional Project Award
6 · The paper itself

Abstract

backgroundPAM50 gene profiling assigns each cancer to a single intrinsic subtype. However, individual cancers vary in their adherence to a prototype, and due to bulk tissue sampling, some may exhibit expression patterns that indicate intra-tumor admixture of multiple subtypes. Our objective was to develop admixture metrics from PAM50 gene expression profiles in order to stratify Luminal A (LumA) cases according to their degree of subtype admixture, and then relate such admixture to clinical and molecular variables.

methodsWe re-constructed scaled, normalized PAM50 profiles for 1980 cases (674 LumA) in the METABRIC cohort and for each case computed its Mahalanobis (M-) distance from its assigned centroid and M-distance from all other centroids. We used t-SNE plots to visualize overlaps in subtype clustering. With Normal-like cases excluded, we developed two metrics: Median Distance Criteria (MDC) classified pure cases as those located within the 50th percentile of the LumA centroid and > =50th percentile from any other centroid. Distance Ratio Criteria (DRC) was computed as the ratio of M-distances from the LumA centroid to the nearest non-assigned centroid. Pure and admixed LumA cases were compared on clinical/molecular traits. TCGA LumA cases (n = 509) provided independent validation.

resultsCompared to pure cases in METABRIC, admixed ones had older age at diagnosis, larger tumor size, and higher grade and stage. These associations were stronger for the DRC metric compared to MDC. Admixed cases were associated with HER2 gain, high proliferation, higher PAM50 recurrence scores, more frequent TP53 mutation, and less frequent PIK3CA mutation. Similar results were observed in the TCGA validation cohort, which also showed a positive association between admixture and number of clonal populations estimated by PyClone. LumA-LumB confusion predominated, but other combinations were also present. Degree of admixture was associated with overall survival in both cohorts, as was disease-free survival in TCGA, independent of age, grade and stage (HR = 2.85, Tertile 3 vs.1).

conclusionsLuminal A breast cancers subgrouped based on PAM50 subtype purity support the hypothesis that admixed cases have worse clinical features and survival. Future analyses will explore more extensive genomic metrics for admixture and their spatial significance within a single tumor.

Indexed as

Biomarkers, TumorAgedAged, 80 and overBreast NeoplasmsCluster AnalysisComputational BiologyFemaleGene Expression ProfilingHumansMiddle AgedNeoplasm MetastasisNeoplasm StagingPrognosisProportional Hazards ModelsReproducibility of ResultsTranscriptomeBiomarkers, TumorIntratumor heterogeneityIntrinsic subtypeLuminal aPAM50

Identifiers

PMID30849944
PMCPMC6408846

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.